Eva is a Postdoctoral Fellow in the Infection Analytics Program at the Kirby Institute, UNSW.
She has a background in mathematical biology and received her doctoral degree in 2019 from the Technical University of Munich. In her research, she uses mathematical and quantitative methods to gain a better understanding of within host dynamics of infectious diseases (malaria and SARS-CoV-2) and immunity. In previous projects, she has, e.g., investigated the efficacy of passive antibody treatment...
Eva is a Postdoctoral Fellow in the Infection Analytics Program at the Kirby Institute, UNSW.
She has a background in mathematical biology and received her doctoral degree in 2019 from the Technical University of Munich. In her research, she uses mathematical and quantitative methods to gain a better understanding of within host dynamics of infectious diseases (malaria and SARS-CoV-2) and immunity. In previous projects, she has, e.g., investigated the efficacy of passive antibody treatments against SARS-CoV-2, the risk of resistance against a novel antimalarial drug, the role of immunity in seasonal malaria infections, and different mechanisms of malaria relapses.
Eva has quantified the relationship between the neutralizing antibody level after treatment with monoclonal antibodies (mAbs) and efficacy for preventing COVID-19. This work provides a tool for the rapid prediction of mAb treatment efficacy with the emergence of new SARS-CoV-2 variants and led to her membership in the Australian National Clinical Evidence Taskforce.
Currently, Eva's research focuses on analyzing the risk of SARS-CoV-2 infections in immunosuppressed patients. Using statistical analysis and model fitting of published vaccine effectiveness data, she explores the effect of different conditions and treatments on vaccine effectiveness in immunosuppressed patients. Moreover, she investigates how assay-related differences impact the measured level of neutralization (a known correlate of protection for SARS-CoV-2).
